Conference Call Participants
Stephanie Diaz – Vida Strategic Partners, Inc.
Steven Seedhouse – Cantor Fitzgerald & Co., Research Division
Joon Lee – Truist Securities, Inc., Research Division
Ryan Deschner – Raymond James & Associates, Inc., Research Division
Annabel Samimy – Stifel, Nicolaus & Company, Incorporated, Research Division
Hardik Parikh – JPMorgan Chase & Co, Research Division
Jay Olson – Oppenheimer & Co. Inc., Research Division
Mayank Mamtani – B. Riley Securities, Inc., Research Division
Rohit Bhasin – Morgan Stanley, Research Division
Yale Jen – Laidlaw & Company (UK) Ltd., Research Division
Jiale Song – Jefferies LLC, Research Division
Tsan-Yu Hsieh – William Blair & Company L.L.C., Research Division
Justin Zelin – BTIG, LLC, Research Division
Presentation
Operator
Welcome to the Viking Therapeutics Third Quarter 2025 Financial Results Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded today, October 22, 2025.
I would now like to turn the conference over to Viking’s Manager of Investor Relations, Stephanie Diaz. Please go ahead, Stephanie.
Stephanie Diaz
Vida Strategic Partners, Inc.
Hello, and thank you all for participating in today’s call. Joining me today is Brian Lian, Viking’s President and CEO; and Greg Zante, Viking’s CFO.
Before we begin, I’d like to caution that comments made during this conference call today, October 22, 2025, will contain forward-looking statements under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including statements about Viking’s expectations regarding its development activities, time lines and milestones.
Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially and adversely and reported results should not be considered as an indication of future performance. These forward-looking statements speak only as
